Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why, is it not true? Figures....I got out at $2.40 so it doesn’t really matter but was hoping for 5 bucks. I check in every once in a while
Gonna report this for fraud lol
$COCP BARDA funding BOOM will be any day!!! $10-15
$COCP Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
Published: Jun 23, 2021
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- CoCrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021.
“We are highly encouraged by the potential of CC-42344 to treat seasonal and pandemic influenza,
both of which are major global health concerns,”
said Sam Lee, Ph.D., Cocrystal’s President and interim co-CEO.
“We recently completed a 14-day GLP toxicology study,
which was the final pre-IND enabling step prior to advancing this
potent inhibitor into a first-in-human study.
“There is a pressing need for new antivirals to treat influenza, as currently approved antiviral therapeutics are prone to viral resistance,” added Dr. Lee.
“CC-42344 stops the first step of viral replication by binding to a highly conserved PB2 site of the influenza polymerase complex that is essential to replication.
This uniquely positions CC-42344 to be an effective therapeutic
against all significant A strains of the influenza virus, including avian pandemic strains as well as strains that are resistant to
Tamiflu® (oseltamivir) and
Xofluza® (baloxavir marboxil).”
“The planned Phase 1 study with CC-42344 will be conducted in Australia, which offers favorable regulatory policies and a clinical trial environment that aligns with our strategy for quickly and cost-efficiently moving into clinical development,” said James Martin, Cocrystal’s CFO and interim co-CEO.
“The Australian regulatory agency allows for a streamlined path for early-stage study initiation and the Australian government offers generous incentives for clinical studies performed in that country. Importantly, clinical studies conducted in Australia have a reputation for generating high-quality data.
In preparing to initiate this study, we have already established a subsidiary in Australia and have selected a contract research organization.”
According to the World Health Organization (WHO) estimates, approximately 1 billion people are infected with seasonal
influenza annually, resulting in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths worldwide.
Approved influenza therapies have limited efficacy due to drug resistance and viral mutation.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target
the replication process of coronaviruses (including SARS-CoV-2), influenza viruses,
hepatitis C viruses and
noroviruses.
Cocrystal employs unique structure-based technologies and
Nobel Prize-winning expertise to create first
- and best-in-class antiviral drugs.
For further information about Cocrystal, please visit http://www.cocrystalpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy with respect to the clinical development of CC-42344, including the planned initiation of influenza A Phase 1 study in Australia in the third quarter of 2021, and the potential of CC-42344 to treat seasonal and pandemic influenza. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from the impact of the COVID-19 pandemic on the Australian and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
Cocrystal Pharma Inc (COCP)
1.2 ? 0.05 (4.35%)
Volume: 1,051,233 @07/09/21 7:42:54 PM EDT
Bid Ask Day's Range
1.18 3.25 1.13 - 1.2
COCP Detailed Quote
LOWBALL PPS HERE MY FRIEND $COCP
Still waiting for sub-buck.
Sideway then BOOOOM .
EVERYDAY ENTERED ON DIPS
Loading all the cheap shares, long weekend coming, should have a nice sale .
DIS GOOD NEWS Cocrystal Pharma added to Russell Microcap Index Seeking Alpha - 6/28/2021 9:28:10 AM
HI DARE, BEEN PICKING @ SOME LOWBALL PPS Cocrystal Pharma Inc. (COCP)'
Cocrystal Pharma Inc (COCP)
1.26 ? -0.05 (-3.82%)
Volume: 1,635,660 @06/30/21 7:20:45 PM EDT
Bid Ask Day's Range
1.25 1.27 1.24 - 1.3
COCP Detailed Quote
i am ah dipper picker $COCP
COCP Rocket Ship To The Stars and you had 15 months for the opportunity to build to add and most will never understand the true power of biotech on this BARDA news otw
i can see $5.00 plus 'Cocrystal Pharma Inc. (COCP)' buyout ????? anyone ?????
re;
BUY as much COCP as humanly possible...its been a long war but the final battle in now in progress and move higher then you can imagine
Agree, loading and holding .
$COCP
How high and when should I imagine?
BUY as much COCP as humanly possible...its been a long war but the final battle in now in progress and move higher then you can imagine
GOOD MESSAGE;'Cocrystal Pharma Inc. (COCP)'
Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants
Jun. 14, 2021 9:15 AM ETCocrystal Pharma, Inc. (COCP)By: Mamta Mayani, SA News Editor
Cocrystal Pharma (NASDAQ:COCP) jumps 11.2% premarket after announcing that its protease inhibitor CDI-45205 is active against SARS-CoV-2 and two variants.
Two reference inhibitors including remdesivir and PF-00835231 were included in the study as comparators.
Results showed CDI-45205 had excellent antiviral activity against the U.K. variant, with an EC50 of 1.9 uM (remdesivir EC50 0.6 uM; PF-00835231 EC50 >100 uM) and against the South African variant, with an EC50 of 2.5 uM (remdesivir EC50 0.8 uM; PF-00835231 EC50 >100 uM) in the absence of a P-glycoprotein efflux inhibitor.
In mouse and rat pharmacokinetic studies, CDI-45205 showed good bioavailability, and also no cytotoxicity against a variety of human cell lines.
Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-infected mice.
Now read: Cocrystal Pharma EPS in-line
yes goodies here Book/sh $0.73 selling less than 2x's book value 'Cocrystal Pharma Inc. (COCP)' with $33 mil. cash cow thing
Long term investment, huge potential .
almost two wks since [IN MEMORIAM Gary Wilcox, Ph.D. 1947-2021. Chairman, CEO,]
passed on.
major team still on lives on.
'Cocrystal Pharma Inc. (COCP)'
reporting more cash than last qtr. $33.0 million as of December 31, 2020.
Cocrystal Pharma Inc. (COCP)
expecting more cash wit royalty payments from merck MRK
higher cash reported in last filing $31.8mil,recent $33.0 million as of December 31, 2020.
$COCP CASH COW, $31.781M Cash Reading DD & Theory NEWS RELEASE 3-AUG-2020 New published study from K-State virologists identifies potential COVID-19 treatment
KANSAS STATE UNIVERSITY
https://www.cocrystalpharma.com/
Cash Cow my friend The Company reported cash and cash equivalents of $33.3 million as of March 31, 2021,
compared with $33.0 million as of December 31, 2020.
The Company reported working capital of $32.2 million as of March 31, 2021.
dats ah lot of doe re me $$$$$ cocp
Cocrystal Pharma EPS in-line
May 17, 2021 8:33 AM ETCocrystal Pharma, Inc. (COCP)Cocrystal Pharma, Inc. (COCP)By: Mamta Mayani, SA News Editor
Cocrystal Pharma (NASDAQ:COCP): Q1 GAAP EPS of -$0.04 in-line.
Cash and cash equivalents of $33.3M
Press Release
Now read: Vaccinex reports Q1 results
https://seekingalpha.com/news/3697050-cocrystal-pharma-eps-in-line?utm_source=advfn.com&utm_medium=referral
https://seekingalpha.com/pr/18319968-cocrystal-pharma-reports-first-quarter-2021-financial-results-and-provides-business-update
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
May 17, 2021 8:00 AM ETGlobeNewswireCocrystal Pharma, Inc. (COCP)
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, reports financial results for the three months ended March 31, 2021 and provides updates on its antiviral pipeline and business activities.
“We believe Cocrystal is well-positioned to advance the discovery and development of novel antiviral compounds to address major global medical concerns and create significant market opportunities for our company,” said Gary Wilcox, Ph.D., Chairman and Chief Executive Officer of Cocrystal. “Following the successful financing completed earlier this month, we believe we have sufficient capital to fund our currently planned operations and product development programs through 2024.”
“We remain on track to achieve key milestones this year with our coronavirus, norovirus and influenza A antiviral programs,” said Sam Lee, Ph.D., President of Cocrystal. “As discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds. We recently demonstrated strong in vitro synergistic effect between remdesivir and our protease inhibitor CDI-45205 and are currently examining in vitro activity of our SARS-CoV-2 3CL protease inhibitors against emerging SARS-CoV-2 variants.
“We also expect to report initial proof-of-concept mouse-model read-out with our norovirus protease inhibitors next month,” added Dr. Lee. “We believe that by targeting viral protease we may develop an effective treatment for norovirus gastroenteritis. This is a significant opportunity for Cocrystal given the lack of any effective antiviral treatment or vaccine for norovirus gastroenteritis, and the limited ability to curtail outbreaks of this highly contagious virus that causes symptoms of acute gastroenteritis.
“With our program for the treatment of seasonal and pandemic influenza, we are completing the remaining IND-enabling studies with CC-42344 with preparations underway to initiate a Phase 1 study in the third quarter of this year. We look forward to providing additional details about this program including announcing our clinical strategy,” Dr. Lee concluded.
Antiviral Development Pipeline Milestones and Updates
COVID-19 Programs
In December 2020 we announced the selection of CDI-45205 as the lead compound for further development against coronaviruses including SARS-CoV-2, that causes COVID-19. CDI-45205 was one of the broad-spectrum protease inhibitors that were obtained from Kansas State University Research Foundation (“KSURF”) under an exclusive license agreement announced in April 2020. That agreement provides Cocrystal with an exclusive, royalty-bearing license to develop and commercialize therapeutic, diagnostic and prophylactic products against coronaviruses, caliciviruses and picornaviruses based on antivirals discovered by KSURF. The Company believes the 3CL protease has the ability to convert the inactive SARS-CoV-2 replication enzymes into the active form. CDI-45205 showed good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection, and also no cytotoxicity against a variety of human cell lines.
The Company recently demonstrated a strong in vitro synergistic effect with the FDA-approved COVID-19 medicine remdesivir. Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-2 infected mice. The Company has initiated scale-up synthesis and process chemistry development and is working toward pre-IND status with CDI-45205.
Cocrystal has leveraged its antiviral development expertise by using its proprietary technology and drug discovery platform to launch two additional COVID-19 programs, novel SARS-CoV-2 3CL protease inhibitors and replication inhibitors. The Company anticipates identifying another SARS-CoV-2 preclinical 3CL lead for oral administration this year.
By targeting the viral replication enzymes and proteases, Cocrystal believes it is possible to develop effective treatments for all coronaviruses that cause COVID-19, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
Influenza A Program
Completing IND-enabling activities with CC-42344 with planned Phase 1 study initiation during the third quarter of 2021. CC-42344 showed excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu-resistant strains, and has a favorable pharmacokinetic profile.
Influenza remains a major global concern. The World Health Organization (WHO) estimates approximately 1 billion cases of influenza annually worldwide, resulting in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths. Approved influenza therapies have major limitations due to drug resistance and viral mutation. Cocrystal is designing influenza drug candidates to be active against drug-resistant strains, effective against future mutations and available through multiple routes of administration including oral, inhalation and injection.
Hepatitis C Program
We have been seeking a partner to advance the development of CC-31244 since completing Phase 2a trials. This compound showed favorable safety and preliminary efficacy in a triple regimen Phase 2a study in combination with Epclusa (sofosbuvir/velpatasvir) for the ultra-short treatment of individuals infected with the hepatitis C virus (HCV). To date, no other company has developed a short-duration HCV treatment of 4 weeks or less with a high (>95%) sustained virologic response (SVR) at week 12.
HCV is a viral infection of the liver that causes both acute and chronic infection. According to the WHO, in 2017 HCV chronically affected an estimated 71 million people worldwide, including 3.5 million in the U.S. Approximately 399,000 people die each year from hepatitis C infection, mostly from cirrhosis and hepatocellular carcinoma.
Norovirus Program
Completion of a proof-of-concept animal study is expected in the second quarter of 2021 with a broad-spectrum norovirus protease polymerase inhibitor. Cocrystal is further developing certain proprietary broad-spectrum antiviral compounds to treat norovirus infections under its license agreement with KSURF.
Norovirus is a public health problem responsible for nearly 90% of epidemic, non-bacterial outbreaks of gastroenteritis around the world. Norovirus is a very common and highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea.
First Quarter 2021 and Recent Highlights
Licensing and Collaboration Agreements
Completed all research obligations under the Merck exclusive worldwide license and collaboration agreement for influenza A/B antiviral compounds. As of mid-January 2021, Merck assumed all responsibility for further program development.
Extended a drug discovery collaboration with HitGen and InterX, combining three independent platforms to discover and optimize molecules that may lead to novel antiviral drug candidates.
Research and Development
Continued IND-enabling studies with influenza PB2 inhibitor CC-42344 in preparation for initiating a Phase 1 clinical study in the third quarter of 2021.
Developed scale-up synthesis of SARS-CoV-2 3CL protease inhibitor CDI-45205.
Initiated SARS-CoV-2 3CL oral protease inhibitor program.
Initiated SARS-CoV-2 replication inhibitor program.
Continued proof-of-concept mouse norovirus model study with expected initial read-out in June 2021.
Scientific Presentation
Presented an overview of Cocrystal’s drug discovery platform technology, including its unique ability to develop broad-spectrum antiviral therapeutics and its advantages compared with the traditional drug discovery and development process, at the “reimagine Health Research Symposium” in January 2021.
Financial Developments
In May 2021, completed raise of $36.4 million in net proceeds from a public offering of common stock.
First Quarter Financial Results
Throughout 2020 Cocrystal reported quarterly revenues under an influenza A/B collaboration with Merck consisting of research and development (R&D) services performed by Cocrystal and reimbursed by Merck. In mid-January 2021 Merck assumed all activities and expenses associated with the continued development of the influenza A/B compounds discovered under this collaboration. As anticipated, Cocrystal reported no revenues for the first quarter of 2021 compared with $461,000 in revenues for the first quarter of 2020. Under the terms of the Merck collaboration, Cocrystal is eligible to receive up to $156 million in future payments related to designated development, regulatory and sales milestones, as well as royalties on product sales.
R&D expenses for the first quarter of 2021 were $1.6 million compared with $1.3 million for the first quarter of 2020, with the increase primarily related to increased spending on our COVID-19 and influenza programs. General and administrative expenses for the first quarter of 2021 were $1.2 million versus $1.1 million for the prior-year quarter, with the increase primarily due to insurance and professional fees.
The net loss for the first quarter of 2021 was $2.7 million, or $0.04 per share, compared with a net loss for the first quarter of 2020 of $2.0 million, or $0.05 per share.
The Company reported cash and cash equivalents of $33.3 million as of March 31, 2021, compared with $33.0 million as of December 31, 2020. The Company reported working capital of $32.2 million as of March 31, 2021.
In May 2021, Cocrystal closed an underwritten public offering of 26,000,000 shares of common stock at a price to the public of $1.54 per share, and received net proceeds of approximately $36.4 million less underwriting discounts and commissions.
About Cocrystal Pharma, Inc. (PCYC)
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected future success of our discovery and development activities in addressing major global medical concerns, the expected achievement of key milestones in our antiviral programs and the anticipated timing of achieving such milestones, including reporting proof-of-concept mouse-model read-out with our norovirus protease inhibitors in June 2021, the planned initiation of the influenza A Phase 1 study during the third quarter of 2021, identifying another SARS-CoV-2 preclinical 3CL lead for oral administration in 2021, and our plans regarding the expected completion of a norovirus proof-of-concept animal study in the second quarter of 2021; our expectations and estimates regarding the future applications and effectiveness of, and the market opportunities for, our product candidates; the expected results of Cocrystal’s extended collaboration with HitGen and InterX; and future liquidity. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from the impact of the COVID-19 pandemic on the national and global economy, on our collaboration partners and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, our reliance on Merck for further development in the influenza A/B program under the license and collaboration agreement, HitGen’s DNA Encoded Library technology and InterX’s software performing as expected, the results of future preclinical and clinical studies, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
COCRYSTAL PHARMA, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
https://seekingalpha.com/pr/18319968-cocrystal-pharma-reports-first-quarter-2021-financial-results-and-provides-business-update
#2- reading on Cocrystal Pharma Inc. (COCP)' 06-09-2021
https://finance.yahoo.com/news/cocrystal-pharma-participation-noble-capital-183000453.html
Cocrystal Pharma, Inc.
Wed, June 9, 2021, 11:30 AM·4 min read
COCP
-0.4032%
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE)
-- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses,
the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management’s participation in the Noble Capital Markets C-Suite Interview Series is now available online.
During the 30-minute video interview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer,
Cocrystal discussed its antiviral drug-discovery and development work and provided program updates.
“Cocrystal utilizes a proprietary structure-based technology
platform to discover viral inhibitors that address underserved
medical needs in very large markets including pandemics
and widespread viral infections,” said Sam Lee, Ph.D., interim co-CEO and President.
“This powerful platform differentiates Cocrystal’s approach and
allows us to focus on three important drug-discovery processes
including improvements with in vitro potency,
broad-spectrum activity and drug-resistance profile.
It is very difficult to improve these critical processes with traditional drug discovery tools.”
“We are aggressively moving forward our antiviral programs with
multiple upcoming milestones including results from the
proof-of-concept animal study with our norovirus program expected
later this month,
the planned initiation of a Phase 1 influenza A clinical study in
the third quarter and advancing our COVID-19 programs toward pre-IND status,”
added James Martin, interim co-CEO and CFO.
“Given our cost-efficient structure and financial resources,
we believe we have sufficient capital to fund current operations
and planned program activities through 2024.
The possibility of milestone payments under our Merck collaboration would extend that cash runway.
We do not expect to raise additional capital in 2021 and for some time beyond.”
Story continues;
Cautionary Note Regarding Forward-Looking Statements
This press release and the interview referenced above contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding the expected future success of our discovery and development activities in addressing major global
medical concerns;
the expected achievement of key milestones in our antiviral programs
and the anticipated timing of achieving such milestones, including reporting results from the proof-of-concept animal study in our norovirus program expected in June 2021, the planned initiation of
the influenza A Phase 1 study during the third quarter of 2021, identifying another SARS-CoV-2 preclinical lead for oral administration in 2021, and advancing the COVID-19 programs toward pre-IND status with potential to initiate clinical testing in 2022;
our expectations and estimates regarding the future applications and effectiveness of, and the market opportunities for, our product candidates;
potential receipt of milestone payments and royalties under the collaboration agreement with Merck Sharp & Dohme Corp.,
our plans with respect to future capital raising activities and
expected liquidity .
The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements.
We have based these forward-looking statements largely on our current expectations and projections about future events.
Some or all of the events anticipated by these forward-looking statements may not occur.
Important factors that could cause actual results to differ from those in the forward-looking statements include,
but are not limited to the risks arising from the impact of the
COVID-19 pandemic on the national and global economy, on our collaboration partners and on our Company, including supply chain disruptions and our continued ability to proceed with our programs,
our reliance on Merck for further development in the influenza A/B program under the collaboration agreement and Merck’s further research and internal priorities,
the results of future preclinical and clinical studies, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes,
and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government.
Further information on our risk factors is contained in our filings
with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us
herein speaks only as of the date on which it is made.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them.
We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
# # #
good morning reading on Cocrystal Pharma Inc. (COCP)' 06-09-2021
https://finance.yahoo.com/news/cocrystal-pharma-participation-noble-capital-183000453.html
4COCP chart reads tweezer call https://www.level2stockquotes.com/level-ii-quotes.html
good reads here peter https://finviz.com/quote.ashx?t=cocp
[-chart]www.cocrystalpharma.com/development-pipeline/coronavirus/coronavirus-replication-and-protease-inhibitor[/chart]
https://www.cocrystalpharma.com/development-pipeline/overview
IN MEMORIAM Gary Wilcox, Ph.D. 1947-2021. Chairman, CEO, Co-Founder and Beloved Colleague
'Cocrystal Pharma Inc. (COCP)'
Ceo dies and stocks goes up,seems wrong but I'll take it!!!!
IT DIPPED SOME BUT RALLYING TODAY Cocrystal Pharma Inc. (COCP)' HUGE PIPELINE
Cocrystal Pharma Inc (COCP)
1.1041 ? -0.0059 (-0.53%)
Volume: 1,717,002 @05/26/21 12:12:08 PM EDT
Bid Ask Day's Range
1.1 1.11 1.08 - 1.11
COCP Detailed Quote
COCP mention plus a couple others worth a look
https://www.zerohedge.com/news/2021-05-14/investing-biotech-now-right-time
wow did you get any Cocrystal Pharma Inc. (COCP)'
Let’s see how it work out tomorrow
I placed 50,000 shares at $1 for a lotto play
Followers
|
103
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3013
|
Created
|
09/05/13
|
Type
|
Free
|
Moderators |
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses,
influenza viruses, and noroviruses.. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated
in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and
collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the
treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early discovery program
to identify and develop novel antivirals for the treatment of norovirus gastroenteritis.
Our proprietary structural biology, enzymology and medicinal chemistry expertise enable us to develop novel antiviral agents.
These technologies and our market-focused approach to drug discovery are designed to effectively create small molecule therapeutics
that are safe, effective and convenient to administer.
Our technology provides a 3-D structure of inhibitor complexes at near-atomic resolution and immediate insight to guide SAR.
This helps us identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement.
For any given viral disease, there are different subtypes of viruses that cause the disease. For example, there are six different subtypes of virus that cause hepatitis C.
In hepatitis C, these subtypes are termed "genotypes." Each hepatitis C genotype is common in some parts of the world and rare in others.
Our technology allows us to develop drug candidates that are effective against all subtypes of a given virus. The drug candidate is called broad spectrum.
Viral resistance is a major obstacle to developing effective antiviral therapies that target viral molecules. Viruses reproduce rapidly and in enormous quantities.
During reproduction, random variations in viral molecules called mutations spontaneously develop. If such a mutation occurs in a viral molecule that is targeted
by an antiviral therapy that therapy may no longer be effective against the mutated virus. These mutated or "resistant viruses" can freely infect and multiply even
in individuals who have received treatment. In some cases, resistant virus strains may even predominate. For example, in the 2009 swine influenza pandemic,
the predominant strain was resistant to the best available therapies.
To overcome this obstacle, we identify and target critical components of viral replication enzymes that are crucial to the function of the enzyme and sensitive to change.
Any mutation in these critical enzyme components is likely to inactivate the enzyme and, in turn render the virus incapable of replicating. We test the effectiveness of
our compounds against potential viral mutations and select compounds with the highest barrier to resistance.
Patients at risk for suffering from many viral infections have few effective antiviral treatments from which to choose. Furthermore, some available treatment options have characteristics that limit their market potential. They are either priced too high, poorly tolerated, inconvenient to administer, ineffective against some viral subtypes or prone to emergence of resistance.
Our technology is based on the work of our Chief Scientist and Chairman of our Scientific Advisory Board, Dr. Roger Kornberg, and Dr. Raymond Schinazi.
Dr. Kornberg was awarded the 2006 Nobel Prize for Chemistry for his work to visualize a replication enzyme called RNA polymerase in action.
Using techniques called protein cocrystallization and X-ray crystallography, Dr. Kornberg and his colleagues generated three dimensional pictures
similar to the one on the left of RNA being transcribed by an RNA polymerase.
Dr. Schinazi is a world-class expert in discovering novel nucleoside therapeutics. He co-founded several successful antiviral companies including
Triangle Pharmaceuticals Inc., Idenix Pharmaceuticals Inc. and Pharmasset, Inc.
We are leveraging both Dr. Kornberg's and Dr. Schinazi's expertise in these methods to identify and develop new antiviral compounds.
Using these methods, our scientists are able to:
Influenza is a severe respiratory illness caused by either the influenza A or B virus that results in outbreaks of disease mainly during the winter months.
Currently approved antiviral treatments for influenza are partially effective and prone to viral resistance. Strains of flu virus that are resistant to approved treatments,
osteltamivir (Tamiflu™), zanamavir (Relenza™) and Xofluza have appeared and in some cases are predominant.
For example, the predominant strain of the 2009 swine influenza pandemic was resistant to Tamiflu™.
These drugs target one of two viral proteins, hemagglutinin or neuraminidase, neither of which is highly conserved between viral strains.
In fact, different influenza virus strains such as H1N1 and H5N1 are named by their respective differences in hemagglutinin (H) and neuraminidase (N) proteins.
The ability of the influenza virus to produce viable variants of these two proteins is the key to its ability to develop resistance.
To learn more about influenza, please visit the information page at the Center for Disease Control and Prevention (CDC).
References: https://www.cdc.gov/flu/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |